Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.42 |
| ▸ | CHRNG | P07510 | 2/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRND | Q07001 | 2/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8082348 | 0.90 | DRD2 (0.50) | DRD2DRD4DRD3OPRM1OPRD1 | |
| SCHEMBL1155345 | 0.87 | OPRM1 (0.50) | DRD2DRD4DRD3OPRM1OPRD1 | |
| SCHEMBL27681431 | 0.83 | SLC6A4 (0.54) | DRD2DRD4DRD3OPRM1OPRD1 | |
| SCHEMBL28323043 | 0.83 | SLC6A3 (0.50) | DRD2DRD4DRD3OPRM1OPRD1 | |
| SCHEMBL1154800 | 0.81 | SLC6A4 (0.57) | DRD2DRD4DRD3OPRM1OPRD1 | |
| SCHEMBL655758 | 0.81 | DRD2 (0.66) | DRD2OPRM1CCR1SLC6A3SLC6A4 | |
| SCHEMBL8959998 | 0.80 | SLC6A3 (0.42) | DRD2DRD4DRD3OPRM1OPRD1 | |
| SCHEMBL6681808 | 0.80 | DRD2 (0.50) | DRD2DRD3OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL30005276 | 0.79 | DRD2 (0.63) | DRD2OPRM1CCR1SLC6A3SLC6A4 | |
| SCHEMBL2270824 | 0.79 | DRD2 (0.46) | DRD2DRD3OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504327-A | Alpha, beta unsubstituted 1, 4-ketoaldehyde compound, and preparation method and application thereof by non-metal photocatalytic aqueous solution acetaldehyde alpha-site selective single alkylation reaction | 安徽师范大学 | 2025-02-25 | — | — | CN | disclosed |
| WO-2023102022-A1 | 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| EP-2799435-B1 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR | CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-9187430-B2 | Poly (ADP-ribose) polymerase inhibitor | CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-11-17 | — | — | US | disclosed |
| US-6329385-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, VIRAL DISEASES AND GASTROINTESTINAL DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| CN-1289336-A | Chemokine receptor antagonists and methods of use therefor | LEUKOSITE INC (US) | 2001-03-28 | — | — | CN | disclosed |
| EP-1077973-A2 | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS GYOGYSZERGYAR RT. (HU) | 2001-02-28 | — | — | EP | disclosed |
| WO-2001009138-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1049700-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999058527-A2 | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS Gyógyszergyár Rt. (HU) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999037651-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENIUM PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-4252804-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | METABIO-JOULLIE (FR) | 1981-02-24 | — | — | US | disclosed |
| US-4166853-A | Antihypertensive 7-trifluoromethyl-4-aminoquinolones | THE UPJOHN COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | DRD2 3118/4885DRD4 3686/4885DRD3 3184/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | DRD2 4124/4885DRD4 4544/4885DRD3 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.